#cadazolid

[cdifffoundation]

The U.S. FDA Designates Johnson & Johnson's Cadazolid An Orphan Drug For Treatment of C.diff. Infection in Pediatric Patients

The U.S. FDA Designates Johnson & Johnson’s Cadazolid An Orphan Drug For Treatment of C.diff. Infection in Pediatric Patients

The FDA designates Johnson & Johnson’s

cadazolid an Orphan Drug for the treatment of

Clostridium difficile (C. diff) infection

in pediatric patients.

    Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.

Cadazolid is a quinoxolidinone antibiotic being developed by Actelion.

        Source:

Aug. 9, 2017 7:40 AM…

View On WordPress

[amcrasto]

Actelion's novel antibiotic Cadazolid receives US FDA Qualified Infectious Disease Product designation for the treatment of Clostridium difficile-associated diarrhea .

Actelion's novel antibiotic cadazolid receives US FDA Qualified Infectious Disease Product designation for the treatment of Clostridium difficile-associated diarrhea .

CADAZOLID, ACT-179811

1025097-10-2

1-Cyclopropyl-6-fluoro-7-[4-({2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenoxy}methyl)-4-hydroxypiperidin-1-yl]-4-oxo-1,4-dihydroquinolin-3-carboxylic acid

l-cyclopropyl-6-fluoro-7-{4-[2-fluoro-4-(R)-5-hydroxymethyl-2-oxo- oxazolidin-3-yl)-phenoxymethyl]-4-hydroxy-piperidin-l-yl}-4-oxo-l,4-dihydro- quinoline-3-carboxylic acid

Formula C29H

View On WordPress